Sensus Healthcare landed Health Canada approval for its SRT-100, a therapy device designed to non-surgically treat skin cancer in hospitals and private practice settings.
The SRT-100 system features the company’s SharpBeam characteristics, treating targeted lesions while leaving surrounding healthy tissue intact. The device treats non-melanoma skin cancer, providing virtually pain-free treatment according to the press release.
"We consider Canada as one of the foremost authorities in providing cost effective technologies and we are delighted to have the SRT-100 considered as a viable choice," president & CEO Joe Sardano said in prepared remarks. "We are looking forward to working with Canada’s healthcare professionals."
The SRT-100 system is manufactured in the U.S. and has received FDA clearance as well as CE Mark approval.
